Regeneron Pharmaceuticals Inc
REGN: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$599.00 | Zrhqfw | Msbcykky |
Regeneron's Solid Immunology Drug Dupixent and Growing Oncology Pipeline Support a Narrow Moat
Business Strategy and Outlook
Regeneron has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to emerge as a profitable commercial operation and establish a narrow moat. Lead drug Eylea has global sales around $9 billion annually and is approved for wet age-related macular degeneration and other eye-related indications. The drug remains well positioned, as its high-dose formulation should allow it to continue to hold strong market share against biosimilars and Roche's new branded drug, Vabysmo.